WELL Health Technologies Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA94947L1022
CAD
3.99
0.32 (8.72%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About WELL Health Technologies Corp. stock-summary
stock-summary
WELL Health Technologies Corp.
Pharmaceuticals & Biotechnology
WELL Health Technologies Corp is a Canada-based omni-channel digital health company. The Company is primarily engaged in operating primary healthcare facilities, as well as an electronic medical records (EMR) business. The Company provides software as a service (SaaS) EMR services to doctors across Canada. It operates as a national telehealth service and is a provider of digital health, billing and cybersecurity related technology solutions. The Company owns and operates over 20 medical clinics and provides digital EMR software and services to over 2,000 medical clinics across Canada. Its clinics offers a range of services such as walk in appointments, family medicine, sleep apnea facilities, Botox treatments, and women’s clinics. It operates clinics across various cities, including Surrey, Vancouver, North Vancouver, Richmond and Coquitlam. The Company is also engaged in the business of providing secure clinic management, telehealth and practice management software related services.
Company Coordinates stock-summary
Company Details
Suite 200, 322 Water Street , VANCOUVER BC : V6B 1B6
stock-summary
Tel: 1 604 6287266
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.41%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Hamed Shahbazi
Executive Chairman of the Board, Chief Executive Officer
Mr. Kenneth Cawkell
Independent Director
Mr. John Kim
Independent Director
Mr. Thomas Liston
Independent Director
Ms. Tara McCarville
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
357 Million
(Quarterly Results - Jun 2025)
Net Profit:
17 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 1,300 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.55

stock-summary
Return on Equity

-7.35%

stock-summary
Price to Book

1.57